Mobile Phone Technology for Prevention of Mother-to-Child Transmission of HIV: Acceptability, Effectiveness, and Cost
Study Details
Study Description
Brief Summary
Although gains have been made in achieving the health-related Millennium Development Goals (MDG), much is still needed in countries affected by high levels of HIV/AIDS. Prevention of mother-to-child transmission (PMTCT) is a cornerstone strategy in reducing infant mortality from HIV. The study will employ a cluster randomized control trial (cRCT) with 26 health facilities randomized to two arms (intervention or control) to determine the effect of mobile phone technology on completion of key PMTCT milestones from antenatal to six weeks postpartum. The study will examine the acceptability, effectiveness, and cost of implementing a PMTCT-focused mHealth strategy among HIV-infected pregnant women, health workers, and male partners.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Control
|
Behavioral: Control
Health facilities where PMTCT services are available in the traditional clinical setting with HIV testing and counseling, PMTCT support, and enrollment in care and treatment.
|
| Intervention
|
Behavioral: Intervention
In addition to the 'Standard of Care', HIV-infected pregnant women and male partners within the PMTCT program are engaged in multi-directional mobile communication for PMTCT promotion with health care providers.
|
Outcome Measures
Primary Outcome Measures
- The proportion of women who successfully complete key PMTCT transition points from antenatal to six weeks postpartum. [~ 6 months]
- Initiation of Infant prophylaxis, Facility delivery and receipt of results of 6 weeks early infant diagnosis by DNA PCR [~ 6 months]
Secondary Outcome Measures
- Uptake ARV prophylaxis/ART during labor, delivery, and postpartum [~ 6 months]
- Self-reported maternal adherence to ARV prophylaxis/ART during pregnancy [~ 4 months]
- Time to initiation of ARV prophylaxis/ART uptake after initial identification of HIV seropositivity within ANC [~ 1 month]
Eligibility Criteria
Criteria
Inclusion Criteria (female):
-
HIV-positive pregnant women seeking ANC at a study site
-
Up to 32 weeks gestation
-
Own or have access to a mobile phone on which they can receive calls and SMS messages
Exclusion Criteria (female):
- HIV-positive pregnant women who have already initiated antiretroviral treatment
Inclusion Criteria (male):
- Referral by pregnant female partner
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Elizabeth Glaser Pediatric AIDS Foundation | Nairobi | Kenya |
Sponsors and Collaborators
- Elizabeth Glaser Pediatric AIDS Foundation
- World Health Organization, Alliance for Health Policy and Systems Research
- Kenya National AIDS & STI Control Programme
Investigators
- Principal Investigator: John Ong'ech, MBChB, MMed, MPH, Elizabeth Glaser Pediatric AIDS Foundation, UON/KNH
- Principal Investigator: Seble Kassaye, MD, MS, Elizabeth Glaser Pediatric AIDS Foundation
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RPC441